To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers and Autosomal Dominant Polycystic Kidney Disease Subjects
Condition: Autosomal Dominant Polycystic Kidney Interventions: Drug: AL01211 or Placebo (Part A); Drug: AL01211 or Placebo (Part B); Drug: AL01211 or Placebo (Part C) Sponsors: AceLink Therapeutics, Inc.; Novotech (Australia) Pty Limited Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials